We are live on ! Find out more
ENZ

Enzo Biochem, Inc.

Delisted

ENZ was delisted on the 17th of April, 2025.

51 hedge funds and large institutions have $62M invested in Enzo Biochem, Inc. in 2022 Q1 according to their latest regulatory filings, with 3 funds opening new positions, 13 increasing their positions, 14 reducing their positions, and 11 closing their positions.

New
Increased
Maintained
Reduced
Closed

63% more call options, than puts

Call options by funds: $253K | Put options by funds: $155K

0% more funds holding in top 10

Funds holding in top 10: 33 (0)

7% less repeat investments, than reductions

Existing positions increased: 13 | Existing positions reduced: 14

10% less capital invested

Capital invested by funds: $69M → $62M (-$6.98M)

14% less funds holding

Funds holding: 5951 (-8)

73% less first-time investments, than exits

New positions opened: 3 | Existing positions closed: 11

Holders
51
Holders Change
-8
Holders Change %
-13.56%
% of All Funds
0.8%
Holding in Top 10
3
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.05%
New
3
Increased
13
Reduced
14
Closed
11
Calls
$253K
Puts
$155K
Net Calls
+$98K
Net Calls Change
+$323K
Name Holding Trade Value Shares
Change
Change in
Stake
APIM
51
Agate Pass Investment Management
Washington
-$78K -24,292 Closed
E
52
Ergoteles
New York
-$68K -21,032 Closed
HF
53
HRT Financial
New York
-$56K -17,589 Closed
HighTower Advisors
54
HighTower Advisors
Illinois
-$48K -15,000 Closed
ASN
55
Advisory Services Network
Georgia
-$34K -10,500 Closed
Acadian Asset Management
56
Acadian Asset Management
Massachusetts
-$26K -8,279 Closed
Optiver Holding
57
Optiver Holding
Netherlands
-$23K -6,611 Closed
BNP Paribas Financial Markets
58
BNP Paribas Financial Markets
France
-$860 -268 Closed

ENZ Hedge Fund Activity: Q1 2022 in Review

51 of the 6,341 institutional investors tracked by Wall St. Rank reported a position in Enzo Biochem, Inc. (ENZ) for Q1 2022, worth a combined $62M — down 10% from $69M a quarter earlier.

Sellers outnumbered buyers: 11 funds closed out of ENZ and 3 opened new positions — a net loss of 8 holders — while 14 trimmed existing stakes and 13 added.

The largest buyer was Morgan Stanley, adding an estimated $1.51M. The largest seller was AMH Equity, cutting an estimated $1.82M.

  • 51 institutional investors held Enzo Biochem, Inc. (ENZ) as of Q1 2022, down from 59 in Q4 2021.
  • Funds reported $62M of Enzo Biochem, Inc. stock for Q1 2022, down 10% quarter-over-quarter.
  • 3 funds opened new Enzo Biochem, Inc. positions in Q1 2022 and 11 closed out, a net change of -8 holders.
  • The largest Enzo Biochem, Inc. buyer in Q1 2022 was Morgan Stanley, an estimated $1.51M added.
  • The largest Enzo Biochem, Inc. seller in Q1 2022 was AMH Equity, an estimated $1.82M sold.

Based on aggregated 13F filings for Q1 2022.